Licensing · MENA · Announced 23 Jan 2014
Jiangsu Recbio Technology → SPIMACO
Licensing deal between Jiangsu Recbio Technology (China) and SPIMACO (Saudi Arabia), covering REC603, announced 23 Jan 2014. Value: Undisclosed.
Parties: Jiangsu Recbio Technology (China) → SPIMACO (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- 15 MENA countries (incl. Saudi Arabia) — ~380M population covered
- Therapeutic area
- Vaccines
- Asset
- REC603 — recombinant nine-valent HPV vaccine (HPV-9), Hansenula-yeast expression
- Announced
- 23 Jan 2014
Our analysis
Why it matters
SPIMACO moves into innovative vaccines. SPIMACO is known as one of Saudi Arabia's largest generics manufacturers (60+ therapeutic categories, two plants at Qassim and Dammam, 1,750M+ units/year).
This deal takes it into a differentiated, high-value preventive asset — a nine-valent HPV vaccine, the modality regarded as the most effective against HPV, preventing ~90% of cervical cancers and ~90% of anogenital warts.
The full analysis is free to read with a work email on this page.
Source: Recbio Press release